EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 222 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Doctor Wipes Away The Debt Of 200 Cancer Patients January 6, 2021 Educators Raise Money in Memory of Teacher Who Dedicated Herself to... January 19, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib April 30, 2021 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... May 13, 2019 Load more HOT NEWS Coping With the Holidays During COVID-19 and Cancer News on the Passing of the Lymphedema Treatment Act! Better together: improving brain tumour treatment Patient Guide in Prostate Cancer Now Available in Vietnamese
